Adam Cooper

1.4k total citations
38 papers, 1.1k citations indexed

About

Adam Cooper is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Adam Cooper has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Adam Cooper's work include Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (7 papers) and CAR-T cell therapy research (7 papers). Adam Cooper is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (7 papers) and CAR-T cell therapy research (7 papers). Adam Cooper collaborates with scholars based in Australia, United States and Canada. Adam Cooper's co-authors include Matteo S. Carlino, Georgina V. Long, Paul de Souza, Richard Kefford, Richard A. Scolyer, Benjamin Y. Kong, Alexander Guminski, Alexander M. Menzies, Elizabeth Liniker and Serigne Lo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Adam Cooper

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam Cooper Australia 16 669 318 303 292 257 38 1.1k
Shoichiro Ohtani Japan 19 939 1.4× 371 1.2× 375 1.2× 177 0.6× 399 1.6× 92 1.4k
Analía Azaro Spain 18 557 0.8× 569 1.8× 198 0.7× 152 0.5× 295 1.1× 56 1.1k
Maria Libera Ascierto United States 19 677 1.0× 397 1.2× 181 0.6× 577 2.0× 188 0.7× 44 1.2k
Crescenzo D’Alterio Italy 19 849 1.3× 371 1.2× 186 0.6× 533 1.8× 172 0.7× 36 1.3k
Zehang Jiang China 10 723 1.1× 534 1.7× 392 1.3× 365 1.3× 479 1.9× 16 1.3k
K. Papadopoulos United States 16 540 0.8× 598 1.9× 131 0.4× 299 1.0× 215 0.8× 56 1.1k
Jeonghee Cho South Korea 18 518 0.8× 685 2.2× 343 1.1× 175 0.6× 422 1.6× 31 1.2k
Sanjeeve Balasubramaniam United States 17 454 0.7× 280 0.9× 204 0.7× 177 0.6× 149 0.6× 33 920
Shilpen Patel United States 9 989 1.5× 219 0.7× 422 1.4× 287 1.0× 344 1.3× 20 1.3k
Catalin Mihalcioiu Canada 14 422 0.6× 391 1.2× 283 0.9× 155 0.5× 156 0.6× 38 1000

Countries citing papers authored by Adam Cooper

Since Specialization
Citations

This map shows the geographic impact of Adam Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Cooper more than expected).

Fields of papers citing papers by Adam Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Cooper. The network helps show where Adam Cooper may publish in the future.

Co-authorship network of co-authors of Adam Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Cooper. A scholar is included among the top collaborators of Adam Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Cooper. Adam Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Yang, Adam Cooper, Jermaine Coward, et al.. (2024). 478O Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study. Annals of Oncology. 35. S1580–S1580.
3.
Cooper, Adam, Vladimir Andelkovic, Kate Wilkinson, et al.. (2023). 700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors. Annals of Oncology. 34. S487–S487. 2 indexed citations
4.
Gao, Bo, Mark Voskoboynik, Adam Cooper, et al.. (2023). A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer. 129(7). 1041–1050. 5 indexed citations
5.
Childs, Stacy J., Richard S. Yoon, Adam Cooper, et al.. (2023). Time toxicity associated with early phase clinical trial participation. ESMO Open. 8(6). 102046–102046. 16 indexed citations
6.
Zheng, Yulong, Anna Rachelle Mislang, Jermaine Coward, et al.. (2022). Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunology Immunotherapy. 71(10). 2371–2379. 14 indexed citations
7.
Cooper, Adam, Daniel Brungs, Joseph W. Po, et al.. (2021). Human TERT promoter mutations as a prognostic biomarker in glioma. Journal of Cancer Research and Clinical Oncology. 147(4). 1007–1017. 43 indexed citations
8.
Po, Joseph W., Yafeng Ma, Alison W. S. Luk, et al.. (2021). Single-Cell Analysis of BRAFV600E and NRASQ61R Mutation Status in Melanoma Cell Lines as Method Generation for Circulating Melanoma Cells. Methods in molecular biology. 2265. 277–286.
9.
Garrett, Celine, David T. Lynch, Daniel Brungs, et al.. (2020). The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. Cancers. 12(7). 1831–1831. 33 indexed citations
10.
Souza, Paul de, Bo Gao, Mark Voskoboynik, et al.. (2020). 574P Updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours. Annals of Oncology. 31. S490–S490. 3 indexed citations
11.
Mislang, Anna Rachelle, Jermaine Coward, Adam Cooper, et al.. (2020). 157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers. Annals of Oncology. 31. S1300–S1301. 2 indexed citations
12.
Panizza, Benedict, Paul de Souza, Adam Cooper, et al.. (2019). Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine. 50. 433–441. 36 indexed citations
13.
Cooper, Adam, Helen M. McGuire, Thomas C. Jeffries, et al.. (2019). Pembrolizumab for anaplastic thyroid cancer: a case study. Cancer Immunology Immunotherapy. 68(12). 1921–1934. 23 indexed citations
14.
15.
Roohullah, Aflah, Adam Cooper, Anna J. Lomax, et al.. (2018). A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Investigational New Drugs. 36(5). 886–894. 23 indexed citations
16.
Vilain, Ricardo E., Alexander M. Menzies, James S. Wilmott, et al.. (2017). Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research. 23(17). 5024–5033. 191 indexed citations
17.
Siu, Lillian L., Neeltje Steeghs, Tarek Meniawy, et al.. (2017). Preliminary Results of A Phase I/IIA Study of BMS-986156 (GLUCOCORTICOID-Induced Tumour Necrosis Factor Receptor-Related Gene [GITR] AGONIST), Alone and In Combination with Nivolumab in Patients with Advanced Solid Tumours. Asia-Pacific Journal of Clinical Oncology. 13. 116–117. 1 indexed citations
18.
Markman, Ben, Paul L. de Souza, Elizabeth Claire Dees, et al.. (2016). A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2526–2526. 18 indexed citations
19.
Webber, Kate, et al.. (2011). Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal. 41(8). 594–605. 5 indexed citations
20.
Mansfield, Jennifer, Miles Parkes, A. B. Hawthorne, et al.. (2007). A randomized, double‐blind, placebo‐controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Alimentary Pharmacology & Therapeutics. 26(3). 421–430. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shoichiro Ohtani Breakdown of academic impact, for papers by Analía Azaro Breakdown of academic impact, for papers by Maria Libera Ascierto Breakdown of academic impact, for papers by Crescenzo D’Alterio Breakdown of academic impact, for papers by Zehang Jiang Breakdown of academic impact, for papers by K. Papadopoulos Breakdown of academic impact, for papers by Jeonghee Cho Breakdown of academic impact, for papers by Sanjeeve Balasubramaniam Breakdown of academic impact, for papers by Shilpen Patel Breakdown of academic impact, for papers by Catalin Mihalcioiu
Rankless by CCL
2026